The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open label, pilot study of veliparib (ABT-888) and lapatinib in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer.
 
Erica Michelle Stringer-Reasor
Honoraria - Breast Cancer Index; Lilly
Research Funding - Corcept Therapeutics (Inst)
Travel, Accommodations, Expenses - Cascadian Therapeutics
 
Eddy Shih-Hsin Yang
Consulting or Advisory Role - Strata Oncology
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Novartis (Inst)
Other Relationship - Strata Oncology
 
Jori E. May
No Relationships to Disclose
 
Valerie Caterinicchia
No Relationships to Disclose
 
Yufeng Li
No Relationships to Disclose
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)